Shape Biopharmaceuticals Inc. is at the forefront of developing next-generation immunotherapies aimed at addressing chronic diseases with significant unmet medical needs. The company utilizes advanced computational epitope-specific antigen design to create a new class of immunotherapeutic drugs. This approach is complemented by their expertise in protein engineering, which optimizes the immunological and antigenic properties of target antigens. By focusing on antigen engineering technology, Shape Biopharmaceuticals enhances the effectiveness of their therapies, ensuring they are tailored to elicit robust immune responses.

In addition to antigen engineering, Shape Biopharmaceuticals employs innovative nanoparticle-based delivery systems to optimize the formulation of their therapeutics. These tailored delivery systems, combined with specific immunomodulators, are designed to achieve optimal therapeutic responses across diverse patient populations. The company is pioneering the development of structurally defined, 3D optimized engineered nanomedicines that harness the immune system to produce personalized therapeutic antibodies directly within patients, marking a significant advancement in the field of immunotherapy.

United States

Shape Biopharmaceuticals is a next-generation immunotherapy developer. With our ambitious team and network, we strive to create a new class of immunotherapeutic drugs for chronic human diseases with high unmet treatment needs, leveraging computational epitope-specific antigen design and next-generation nanoparticle engineering.

Shape Biopharmaceuticals Inc.

Company Details